C1q and systemic lupus erythematosus - PubMed (original) (raw)
Review
C1q and systemic lupus erythematosus
M J Walport et al. Immunobiology. 1998 Aug.
Abstract
In this chapter we review the association between SLE and C1q. In the first part of the chapter we discuss the clinical associations of C1q deficiency, and tabulate the available information in the literature relating to C1q deficiency and autoimmune disease. Other clinical associations of C1q deficiency are then considered, and we mention briefly the association between other genetically determined complement deficiencies and lupus. In the review we explore the relationship between C1q consumption and lupus and we discuss the occurrence of low molecular weight (7S) C1q in lupus, which raises the possibility that increased C1q turnover in the disease may result in unbalanced chain synthesis of the molecule. Anti-C1q antibodies are also strongly associated with severe SLE affecting the kidney, and with hypocomplementaemic urticarial vasculitis, and these associations are also examined. We address the question of how C1q deficiency may cause SLE, discussing the possibility that this may be due to abnormalities of immune complex processing, which have been well characterised in a umber of different human models. There is clear evidence that immune complex processing is abnormal in patients with hypocomplementaemia, and this is compatible with the hypothesis that ineffective immune complex clearance could cause tissue injury, and this may in turn stimulate an autoantibody response. We have also considered the possibility that C1q-C1q receptor interactions are critical in the regulation of apoptosis, and we explore the hypothesis that dysregulation of apoptosis could explain important features in the development of autoimmune disease associated with C1q deficiency. An abnormally high rate of apoptosis, or defective clearance of apoptotic cells, could promote the accumulation of abnormal cellular products that might drive an autoimmune response. Anti-C1q antibodies have been described in a number of murine models of lupus, and these are also briefly discussed. We focus on the recently developed C1q "knockout" mice, which have been developed in our laboratory. Amongst the C1q deficient mice of a mixed genetic background high titres of antinuclear antibodies were detected in approximately half the animals, and around 25% of the mice, aged eight months had evidence of a glomerulonephritis with immune deposits. Large numbers of apoptotic bodies were also present in diseased glomeruli, and this supports the hypothesis that C1q may have a critical role to play in the physiological clearance of apoptotic cells.
Similar articles
- C1q, autoimmunity and apoptosis.
Botto M, Walport MJ. Botto M, et al. Immunobiology. 2002 Sep;205(4-5):395-406. doi: 10.1078/0171-2985-00141. Immunobiology. 2002. PMID: 12396002 Review. - Complement component c1q and anti-c1q antibodies in theory and in clinical practice.
Potlukova E, Kralikova P. Potlukova E, et al. Scand J Immunol. 2008 May;67(5):423-30. doi: 10.1111/j.1365-3083.2008.02089.x. Epub 2008 Mar 17. Scand J Immunol. 2008. PMID: 18363591 Review. - Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies.
Botto M, Dell'Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, Loos M, Pandolfi PP, Walport MJ. Botto M, et al. Nat Genet. 1998 May;19(1):56-9. doi: 10.1038/ng0598-56. Nat Genet. 1998. PMID: 9590289 - C1q knock-out mice for the study of complement deficiency in autoimmune disease.
Botto M. Botto M. Exp Clin Immunogenet. 1998;15(4):231-4. doi: 10.1159/000019076. Exp Clin Immunogenet. 1998. PMID: 10072632 Review. - [Apoptosis and C1q: possible explanations for the pathogenesis of systemic lupus erythematosus].
Trendelenburg M, Schifferli JA. Trendelenburg M, et al. Z Rheumatol. 2000 Jun;59(3):172-5. doi: 10.1007/s003930070077. Z Rheumatol. 2000. PMID: 10929445 Review. German.
Cited by
- Genetically transitional disease: conceptual understanding and applicability to rheumatic disease.
Niewold TB, Aksentijevich I, Gorevic PD, Gibson G, Yao Q. Niewold TB, et al. Nat Rev Rheumatol. 2024 May;20(5):301-310. doi: 10.1038/s41584-024-01086-9. Epub 2024 Feb 28. Nat Rev Rheumatol. 2024. PMID: 38418715 Review. - Macrophage subpopulations in pediatric patients with lupus nephritis and other inflammatory diseases affecting the kidney.
Sandersfeld M, Büttner-Herold M, Ferrazzi F, Amann K, Benz K, Daniel C. Sandersfeld M, et al. Arthritis Res Ther. 2024 Feb 8;26(1):46. doi: 10.1186/s13075-024-03281-1. Arthritis Res Ther. 2024. PMID: 38331818 Free PMC article. - Cystic fibrosis autoantibody signatures associate with Staphylococcus aureus lung infection or cystic fibrosis-related diabetes.
Yadav R, Li QZ, Huang H, Bridges SL Jr, Kahlenberg JM, Stecenko AA, Rada B. Yadav R, et al. Front Immunol. 2023 Sep 11;14:1151422. doi: 10.3389/fimmu.2023.1151422. eCollection 2023. Front Immunol. 2023. PMID: 37767091 Free PMC article. - Complement component C1q is an immunological rheostat that regulates Fc:Fc[Formula: see text]R interactions.
So EC, Zhou H, Greenwell A, Burch EE, Ji Y, Mérigeon EY, Olsen HS, Bentzen SM, Block DS, Zhang X, Strome SE. So EC, et al. Immunogenetics. 2023 Aug;75(4):369-383. doi: 10.1007/s00251-023-01311-x. Epub 2023 Jun 15. Immunogenetics. 2023. PMID: 37322230 - Complement: Functions, location and implications.
Kareem S, Jacob A, Mathew J, Quigg RJ, Alexander JJ. Kareem S, et al. Immunology. 2023 Oct;170(2):180-192. doi: 10.1111/imm.13663. Epub 2023 May 24. Immunology. 2023. PMID: 37222083 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical